DV Biomed Co. Ltd.
DV Biomed Co., Ltd. manufactures and sells medical-grade skin care products in Taiwan and China. The company provides health and slimming services; and distributes medical aesthetic fillers and aesthetic medical equipment. It also offers functional beverages and supplements, including beauty, slimming, supplements, and other products; skin care; and beauty products and services. The company was f… Read more
DV Biomed Co. Ltd. (6539) - Net Assets
Latest net assets as of June 2025: NT$479.05 Million TWD
Based on the latest financial reports, DV Biomed Co. Ltd. (6539) has net assets worth NT$479.05 Million TWD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$662.75 Million) and total liabilities (NT$183.69 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$479.05 Million |
| % of Total Assets | 72.28% |
| Annual Growth Rate | -15.17% |
| 5-Year Change | -55.62% |
| 10-Year Change | N/A |
| Growth Volatility | 20.63 |
DV Biomed Co. Ltd. - Net Assets Trend (2019–2024)
This chart illustrates how DV Biomed Co. Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for DV Biomed Co. Ltd. (2019–2024)
The table below shows the annual net assets of DV Biomed Co. Ltd. from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$534.21 Million | +12.12% |
| 2023-12-31 | NT$476.48 Million | -25.16% |
| 2022-12-31 | NT$636.70 Million | -45.99% |
| 2021-12-31 | NT$1.18 Billion | -2.07% |
| 2020-12-31 | NT$1.20 Billion | -1.06% |
| 2019-12-31 | NT$1.22 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to DV Biomed Co. Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 58.4% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$127.83 Million | 23.93% |
| Other Components | NT$406.37 Million | 76.07% |
| Total Equity | NT$534.21 Million | 100.00% |
DV Biomed Co. Ltd. Competitors by Market Cap
The table below lists competitors of DV Biomed Co. Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Andira Agro Tbk PT
JK:ANDI
|
$5.66 Million |
|
Solusi Bangun Indonesia Tbk PT
JK:SMCB
|
$5.66 Million |
|
Placoplatre SA
PA:MLPLC
|
$5.66 Million |
|
Bluesky Digital Assets Corp
OTCQB:BTCWF
|
$5.66 Million |
|
Obase Bilgisayar ve Danismanlik Hizmetleri Ticaret A.S.
IS:OBASE
|
$5.65 Million |
|
King's Bay Resources Corp
PINK:KBGCF
|
$5.65 Million |
|
BetterLife Pharma Inc
OTCQB:BETRF
|
$5.65 Million |
|
Plata Latina Minerals Corporation
PINK:PLLMF
|
$5.65 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in DV Biomed Co. Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 476,479,000 to 534,205,000, a change of 57,726,000 (12.1%).
- Net income of 89,078,000 contributed positively to equity growth.
- Dividend payments of 80,427,000 reduced retained earnings.
- Other factors increased equity by 49,075,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$89.08 Million | +16.67% |
| Dividends Paid | NT$80.43 Million | -15.06% |
| Other Changes | NT$49.08 Million | +9.19% |
| Total Change | NT$- | 12.12% |
Book Value vs Market Value Analysis
This analysis compares DV Biomed Co. Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.80x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 3.13x to 0.80x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | NT$16.61 | NT$52.00 | x |
| 2020-12-31 | NT$57.69 | NT$52.00 | x |
| 2021-12-31 | NT$47.88 | NT$52.00 | x |
| 2022-12-31 | NT$26.15 | NT$52.00 | x |
| 2023-12-31 | NT$19.57 | NT$52.00 | x |
| 2024-12-31 | NT$64.92 | NT$52.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently DV Biomed Co. Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 16.67%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 15.53%
- • Asset Turnover: 0.74x
- • Equity Multiplier: 1.45x
- Recent ROE (16.67%) is below the historical average (27.02%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 16.22% | 8.61% | 0.98x | 1.93x | NT$63.74 Million |
| 2020 | 25.04% | 16.64% | 0.99x | 1.52x | NT$181.02 Million |
| 2021 | 25.84% | 16.67% | 0.98x | 1.58x | NT$186.69 Million |
| 2022 | 44.17% | 15.07% | 2.25x | 1.30x | NT$217.59 Million |
| 2023 | 34.19% | 26.32% | 1.04x | 1.25x | NT$115.26 Million |
| 2024 | 16.67% | 15.53% | 0.74x | 1.45x | NT$35.66 Million |
Industry Comparison
This section compares DV Biomed Co. Ltd.'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $3,317,013,700
- Average return on equity (ROE) among peers: 4.53%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| DV Biomed Co. Ltd. (6539) | NT$479.05 Million | 16.22% | 0.38x | $5.66 Million |
| Grape King Bio Ltd (1707) | $2.08 Billion | 18.27% | 0.54x | $415.70 Million |
| Standard Chemical & Pharmaceutical Co Ltd (1720) | $4.20 Billion | 8.11% | 0.48x | $159.99 Million |
| Maywufa Co Ltd (1731) | $1.41 Billion | 2.15% | 1.10x | $41.61 Million |
| Allied Biotech Corporation (1780) | $1.08 Billion | 1.21% | 1.26x | $48.27 Million |
| ScinoPharm Taiwan Ltd (1789) | $10.36 Billion | 2.77% | 0.13x | $179.96 Million |
| GeneFerm Biotechnology Co Ltd (1796) | $396.19 Million | 1.14% | 1.48x | $23.77 Million |
| Easywell Biomedicals Inc. (1799) | $623.80 Million | -23.22% | 0.95x | $82.61 Million |
| LIWANLI Innovation Co Ltd (3054) | $897.52 Million | 5.08% | 0.06x | $51.25 Million |
| YungShin Global Holding Corp (3705) | $5.90 Billion | 12.21% | 0.47x | $295.98 Million |
| TTY Biopharm Co Ltd (4105) | $6.23 Billion | 17.56% | 0.54x | $484.94 Million |